Janus kinases (JAKs) are involved in various signalling pathways exploited by malignant cells. In multiple myeloma (MM), the interleukin-6/JAK/signal transducers and ...
We describe here interim results from a Phase 1/2 study of CYT387, an orally bioavailable JAK1/2 inhibitor that has shown activity in pre-clinical myeloproliferative neoplasm models, 11, 12 for MF ...
MISSISSAUGA, ON, Oct. 11, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today announced that the ...
Results presented at the 52nd American Society of Hematology Annual Meeting "Anemia is the most serious symptom associated with myelofibrosis, so I am highly encouraged by the emerging activity ...
YM BioSciences Inc. has announced it will present preclinical results for its CYT387 JAK1/JAK2 inhibitor program demonstrating that CYT387 possesses an excellent enzymatic potency and selectivity ...
MISSISSAUGA, ON, Nov. 5, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today reported interim results ...
ORLANDO, FL, Dec. 6 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM) today announced positive interim data from the first 60 patients enrolled in the Phase I/II trial for its JAK1/JAK2 inhibitor, ...
YM has reported positive results from a Phase 1/2 clinical trial of CYT387 in 166 patients with myelofibrosis, a life-threatening myeloproliferative disease. Pending completion of the acquisition, ...
- CYT387 suppresses multiple signaling pathways, prevents proliferation and induces apoptosis in myeloma cells - - Results published in July online edition of Leukemia - "Our pre-clinical evaluation ...
MISSISSAUGA, ON, Aug. 10 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX: YM), announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted ...
In the fiercely competitive and risk-laden life sciences industry, what the little-known YM Biosciences (YMI) has achieved in just 12 months caught the attention of a big crowd of investors, analysts, ...
YM BioSciences Inc. YMI is a drug development company advancing a portfolio of hematology and cancer-related products. The company is advancing three clinical-stage products: CYT387, an oral small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results